Compare
Actinium Pharmaceuticals, Inc. vs Incannex Healthcare Inc. vs iBio, Inc. vs Silo Pharma, Inc.
| Latest fiscal year | Actinium Pharmaceuticals, Inc. ATNM | Incannex Healthcare Inc. IXHL | iBio, Inc. IBIO | Silo Pharma, Inc. SILO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2026-06-30 | 2025-12-31 |
| Revenue | $90.0K | $86.0K | $100.0K | $72.1K |
| Revenue growth (YoY) | n/a | +616.7% | -75.0% | 0.0% |
| Gross margin | n/a | n/a | n/a | 38.6% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$33.89M | -$46.88M | -$33.04M | -$4.23M |
| EPS (Diluted) | -$1.09 | -$1.35 | -$0.32 | -$0.50 |
| Operating cash flow | -$24.58M | -$12.51M | -$23.22M | -$4.66M |
| Free cash flow | -$24.68M | -$12.52M | -$23.80M | n/a |
| Cash & equivalents | $48.00M | $15.04M | $56.40M | $4.75M |
| Total assets | $51.77M | $20.45M | $99.11M | $7.61M |
| Total liabilities | $43.94M | $7.06M | $13.40M | $1.30M |
| Shareholders' equity | $7.83M | $13.39M | $85.71M | $6.31M |
| Return on year-end equity | -432.6% | -350.2% | -38.6% | -67.0% |
| Shares outstanding | 31.20M | 194.38M | 55.70M | 13.32M |
Revenue, most recent five fiscal years
| Fiscal year | Actinium Pharmaceuticals, Inc. | Incannex Healthcare Inc. | iBio, Inc. | Silo Pharma, Inc. |
|---|---|---|---|---|
| Latest | $90.0K Ended 2025-12-31 | $86.0K Ended 2025-06-30 | $100.0K Ended 2026-06-30 | $72.1K Ended 2025-12-31 |
| 1 year earlier | n/a | $12.0K Ended 2024-06-30 | $400.0K Ended 2025-06-30 | $72.1K Ended 2024-12-31 |
| 2 years earlier | $81.0K Ended 2023-12-31 | n/a | $225.0K Ended 2024-06-30 | $72.1K Ended 2023-12-31 |
| 3 years earlier | $1.03M Ended 2022-12-31 | n/a | $0 Ended 2023-06-30 | $72.1K Ended 2022-12-31 |
| 4 years earlier | $1.14M Ended 2021-12-31 | n/a | $1.88M Ended 2022-06-30 | n/a |